Regorafenib Okayed for Colorectal Cancer

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2012-118
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2019English

Regorafenib Adjusted Dose for Chilean Patients With Chemoresistant Metastatic Colorectal Cancer: A Case Series

ecancermedicalscience
Cancer ResearchOncology
2018English

Regorafenib (BAY 73-4506) in Advanced Colorectal Cancer: A Phase I Study

British Journal of Cancer
Cancer ResearchOncology
2012English

Angiogenesis Genotyping and Clinical Outcome During Regorafenib Treatment in Metastatic Colorectal Cancer Patients

Scientific Reports
Multidisciplinary
2016English

A Systematic Review and Meta-Analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer

Anticancer Research
MedicineCancer ResearchOncology
2017English

Response to Regorafenib at an Initial Dose of 120 Mg as Salvage Therapy for Metastatic Colorectal Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2017English

Regorafenib in Combination With Silybin as a Novel Potential Strategy for the Treatment of Metastatic Colorectal Cancer

Oncotarget
Oncology
2017English

Real-World Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Real‐World Adherence in Patients With Metastatic Colorectal Cancer Treated With Trifluridine Plus Tipiracil or Regorafenib

Oncologist
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy